Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Enalapril Maleate
Ceva Animal Health Ltd
QC09AA02
Enalapril Maleate
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Cardio Vascular ACE inhibitor
Expired
2005-09-28
Revised: October 2022 AN: 01731/2022 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT PRILENAL 1 mg, tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: ACTIVE SUBSTANCE: Enalapril maleate 1 mg (Which corresponds to 0.764 mg of enalapril base) For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Brown spotted white round tablet. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of mild, moderate or severe congestive heart failure, caused by mitral regurgitation or dilated cardiomyopathy, as an adjunctive therapy with diuretics (furosemide, whether associated or not with digoxin). 4.3 CONTRAINDICATIONS Do not use in case of hypersensitivity to enalapril or to any of the excipients. Do not use in dogs with evidence of cardiac output failure (e.g. aortic stenosis, mitral stenosis, obstructive cardiomyopathy). See section 4.7. 4.4 SPECIAL WARNINGS Pre renal azotemia generally results from hypotension due to cardio-vascular insufficiency. Substances that deplete blood volume, such as diuretics, or with a vasodilator effect, such as ACE inhibitors, may contribute to lowering systemic blood pressure. Revised: October 2022 AN: 01731/2022 Page 2 of 5 This may create a hypotensive state or exacerbate an existing hypotensive situation and result in pre renal azotemia. Dogs with no detectable renal disease may develop mild and transient increases in blood urea nitrogen or serum creatinine when the product is administered concomitantly with a diuretic. The diuretic and/or enalapril dose should be reduced if clinical signs of hypotension or azotemia appear or if the blood concentration of urea nitrogen and/or creatinine increases significantly above the values observed before treatment. Should clinical signs of overdose occur (azotemia) after the dose is increased from once daily to twice daily, the dose should be decreased to once daily. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIA Read the complete document